{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:25:40Z","timestamp":1787808340936,"version":"build-2784847793"},"reference-count":56,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Compass Pathfinder Ltd","award":["Funded and sponsored by Compass Pathfinder Ltd"],"award-info":[{"award-number":["Funded and sponsored by Compass Pathfinder Ltd"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Post-traumatic stress disorder (PTSD) is a debilitating condition for which there are few efficacious treatments. Psilocybin is being studied for use in treatment-resistant depression but has not yet been investigated in PTSD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>The trial\u2019s primary outcome was to investigate the safety and tolerability of single-dose psilocybin in participants with PTSD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a Phase 2, nonrandomized, open-label, multicenter trial. Secondary outcomes were changes in PTSD symptoms (Clinician-Administered PTSD Scale for DSM-5 (CAPS-5); PTSD Checklist for DSM-5 (PCL-5)), functional impairment (Sheehan Disability Scale; SDS) and quality of life (EQ-5D-5L index score).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Amongst the 22 participants enrolled (63.6% female; mean (SD) age, 39.0 (7.91)\u2009years), there was a total of 117 treatment-emergent adverse events (TEAEs); 70 (59.8%) were reported on administration day, of which 64\/70 (91.4%) resolved by the end of the next day. TEAEs commonly included headache (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200911; 50.0%), nausea (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20098; 36.4%), crying (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20096; 27.3%) and fatigue (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20096; 27.3%). There were no serious TEAEs or TEAEs leading to study withdrawal. Pre-post comparisons indicated a clinically meaningful change from Baseline in mean CAPS-5 total score at Week 4 (\u221229.9 (14.06)) and Week 12 (\u221229.5 (15.43)), which was associated with the intensity of psychedelic experience on Day 1. PCL-5 scores showed symptom reduction was rapid and sustained until Week 12. SDS total score and EQ-5D-5L index score showed similar improvements.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Psilocybin at a dose of 25\u2009mg, administered with psychological support, may be safe, well-tolerated and associated with symptomatic improvement in adults with PTSD. Further investigation is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier: NCT05312151<\/jats:p>\n                    <jats:p>(https:\/\/clinicaltrials.gov\/study\/NCT05312151)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811251362390","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T05:05:58Z","timestamp":1756530358000},"page":"139-148","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8183-8558","authenticated-orcid":false,"given":"Niall M.","family":"McGowan","sequence":"first","affiliation":[{"name":"Compass Pathfinder Ltd (A Subsidiary of Compass Pathways Plc), London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4647-8088","authenticated-orcid":false,"given":"James J.","family":"Rucker","sequence":"additional","affiliation":[{"name":"The Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Yehuda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA"},{"name":"James J. Peters Department of Veterans Affairs Medical Center, Bronx, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0727-6822","authenticated-orcid":false,"given":"Manish","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Sunstone Therapies, Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadav Liam","family":"Modlin","sequence":"additional","affiliation":[{"name":"The Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollie","family":"Simmons","sequence":"additional","affiliation":[{"name":"Compass Pathfinder Ltd (A Subsidiary of Compass Pathways Plc), London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Tofil-Kaluza","sequence":"additional","affiliation":[{"name":"Compass Pathfinder Ltd (A Subsidiary of Compass Pathways Plc), London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriya","family":"Das","sequence":"additional","affiliation":[{"name":"Compass Pathways, Inc (A Subsidiary of Compass Pathways Plc), New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1426-2816","authenticated-orcid":false,"given":"Guy M.","family":"Goodwin","sequence":"additional","affiliation":[{"name":"Compass Pathfinder Ltd (A Subsidiary of Compass Pathways Plc), London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.4685"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100538"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-011-0408-2"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.focus.23021016"},{"issue":"19","key":"e_1_3_3_7_1","first-page":"1","article-title":"New WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis","volume":"6736","author":"Charlson F","year":"2019","unstructured":"Charlson F, van Ommeren M, Flaxman A, et al. (2019) New WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis. The Lancet 6736(19): 1\u20139.","journal-title":"The Lancet"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jts.22454"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.15707"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14116","article-title":"The economic burden of posttraumatic stress disorder in the United States from a societal perspective","volume":"83","author":"Davis L","year":"2022","unstructured":"Davis L, Schein J, Cloutier M, et al. (2022) The economic burden of posttraumatic stress disorder in the United States from a societal perspective. J Clin Psychiatry 83(3): 21m14116.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979351"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3390-8"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.11.143"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2022.110"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2017.10.004"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.01.108"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.12.061"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1037\/pst0000231"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2021.01.039"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.3402\/ejpt.v7.31858"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jts.21848"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230884"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291717000708"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2017.03.007"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2019.01.008"},{"issue":"1","key":"e_1_3_3_28_1","article-title":"Psychological therapies for post-traumatic stress disorder in adults: Systematic review and meta-analysis","volume":"11","author":"Lewis C","year":"2020","unstructured":"Lewis C, Roberts NP, Andrew M, et al. (2020a) Psychological therapies for post-traumatic stress disorder in adults: Systematic review and meta-analysis. Eur J Psychotraumatol 11(1): 1729633.","journal-title":"Eur J Psychotraumatol"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/20008198.2019.1709709"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2021.06.001"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62191-6"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01336-3"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02565-4"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1037\/tra0000254"},{"key":"e_1_3_3_35_1","unstructured":"NICE (2019) Position statement on use of the EQ-5D-5L value set for England. Available at: https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/technology-appraisal-guidance\/eq-5d-5l (accessed September 2024)."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/bs7010007"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/1355621021000005937"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1017\/gmh.2022.29"},{"key":"e_1_3_3_39_1","volume-title":"Columbia-suicide severity rating scale (C-SSRS)","author":"Posner K","year":"2008","unstructured":"Posner K, Brent D, Lucas C, et al. (2008) Columbia-suicide severity rating scale (C-SSRS). New York, NY: Columbia University Medical Center 10: 2008."},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00974"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211064720"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.08.095"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1978417"},{"key":"e_1_3_3_44_1","first-page":"100","article-title":"Sheehan disability scale","volume":"2","author":"Sheehan DV","year":"1983","unstructured":"Sheehan DV (1983) Sheehan disability scale. Handb Psychiatr Meas 2: 100\u2013102.","journal-title":"Handb Psychiatr Meas"},{"key":"e_1_3_3_45_1","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan DV","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, et al. (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20): 22\u201333; quiz 34\u201357.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2019.04.009"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012412"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.586682"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1037\/tra0000428"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1037\/h0101781"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2018.00258"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1037\/pas0000486"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.57"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2013.07.001"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X22666231027111147"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251362390","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251362390","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251362390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:03:09Z","timestamp":1782205389000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251362390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/02698811251362390"],"URL":"https:\/\/doi.org\/10.1177\/02698811251362390","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]}}}